Last reviewed · How we verify
Flagyl
At a glance
| Generic name | Flagyl |
|---|---|
| Also known as | Metronidazole Capsules, Metronidazole, Flagyl-Nistatina (Sanofi Aventis) |
| Sponsor | Par Pharmaceutical, Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- WARNING Metronidazole has been shown to be carcinogenic in mice and rats (see PRECAUTIONS ). Unnecessary use of the drug should be avoided. Its use should be reserved for the conditions described in the INDICATIONS AND USAGE section below.
Common side effects
- Nausea
- Headache
- Diarrhea
- Metallic taste
- Anorexia
- Vomiting
- Epigastric distress
- Abdominal cramping
- Constipation
- Dizziness
- Weakness
- Vertigo
Serious adverse events
- Convulsive seizures
- Encephalopathy
- Aseptic meningitis
- Peripheral neuropathy
- Optic neuropathy
- Toxic epidermal necrolysis (TEN)
- Stevens-Johnson Syndrome (SJS)
- Drug reaction with eosinophilia and systemic symptoms (DRESS)
- Acute generalized exanthematous pustulosis (AGEP)
- Hepatotoxicity/acute liver failure
Key clinical trials
- AI Tool to Reduce Clinician Documentation Burden (NA)
- HIFU Versus Myomectomy for the Treatment of Symptomatic Uterine Fibroids (NA)
- SOAR: Surgery Objective Analysis and Review
- Precision Medicine in Alzheimer's Disease : Integration of Resilience Metrics and Risk Factors - Validation Cohort BioCogBank-AD (NA)
- Comparison of Gait Metrics in Patients With Stroke, Traumatic Brain Injury, and Multiple Sclerosis (NA)
- Diaphragmatic Physiology Similarity Index May Titrate HFNC Flow Setting: A Prospective Observational Study (NA)
- The STop UNhealthy Substance Use Now Trial (NA)
- Evaluation of One-Shot Vision Differential Diagnosis (OSVDE) and Multi-Step Conversational Non-Inferiority (MSCNE) in AI Medical Interviewing
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flagyl CI brief — competitive landscape report
- Flagyl updates RSS · CI watch RSS
- Par Pharmaceutical, Inc. portfolio CI